European Heart Journal Advance Access first published online on August 5, 2008
This version published online on August 21, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn362
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
1 TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 350 Longwood Avenue, First Office Floor, Boston, MA 02115, USA
2 Eli Lilly Research Laboratories, Indianapolis, IN, USA
3 Azienda Ospedaliera S. Maria della Misericordia, Udine, Italy
4 3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
5 Cardiology Department, Hospital Universitario La Paz, Madrid, Spain
Received 3 July 2008; revised 15 July 2008; accepted 17 July 2008.
* Corresponding author. Tel: +1 617 278 0145, Fax: +1 617 734 7329, Email: eantman{at}partners.org
Aims: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention. We hypothesized that prasugrel would reduce not only first events but also recurrent primary endpoint events and therefore total events compared with clopidogrel.
Methods and results: Poisson regression analysis was performed to compare the number of occurrences of the primary endpoint between prasugrel and clopidogrel in TRITON-TIMI 38. Landmark analytic methods were used to evaluate the risk of a recurrent primary endpoint event following an initial non-fatal endpoint event. Among patients with an initial non-fatal event, second events were significantly reduced with prasugrel compared to clopidogrel (10.8 vs. 15.4%, HR 0.65, 95% CI 0.46–0.92; P = 0.016), as was CV death following the non-fatal event (3.7 vs. 7.1%, HR 0.46, 95% CI 0.25–0.82; P = 0.008). Overall there was a reduction of 195 total primary efficacy events with prasugrel vs. clopidogrel (rate ratio 0.79, 95% CI 0.71–0.87; P < 0.001). Recurrent bleeding events occurred infrequently (TIMI major non-CABG bleeds: four with prasugrel and two with clopidogrel). Study drug discontinuation was frequent following the initial major bleeding event (42% of patients discontinued study drug).
Conclusion: While standard statistical analytic techniques for clinical trials censor patients who experience a component of the primary composite endpoint, total cardiovascular events remain important to both patients and clinicians. Prasugrel, a more potent anti-platelet agent, reduced both first and subsequent cardiovascular events compared with clopidogrel in patients with ACS.
Key Words: Acute coronary syndrome • Percutaneous coronary intervention • Prasugrel • Clopidogrel
The originally published version of this paper was incorrectly published with standard subscription-based access instead of the Open Access model. This has now been corrected. The publisher wishes to apologize for this error.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555. [Full Text] [PDF]
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koul and D. J. Moliterno Bare-Metal Versus Drug-Eluting Stent Placement Among Patients Presenting With Anemia J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 337 - 338. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Scott, R. M Norwood, and D. Parra P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel Ann. Pharmacother., January 1, 2009; 43(1): 64 - 76. [Abstract] [Full Text] [PDF]
|
|